EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma - Concepedia

Concepedia

Publication | Closed Access

EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma

32

Citations

25

References

2014

Year

Lei Liu, Weijuan Wang, Hui Chen, Yan Zhao, Wei Bai, Zhanxin Yin, Chuangye He, Jia Jia, Man Yang, Jielai Xia,

Clinical Cancer Research

Abstract

The earliest time to evaluate the response to combination therapy is 3 months (median, 94 days) after therapy. EASL and mRECIST responses are independent predictors for OS at this early time point.

References

	Year	Citations

Page 1